He is one of the founders of ProQR, but even long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he still gets enthusiastic when talking about RNA.
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
New therapies are thoroughly tested to ensure safety and efficacy, but for a company like ProQR, which aims to treat small groups of patients with rare diseases, innovating within the system is essential. Jessica is trying to rethink clinical trials.
2017 was a fruitful year for ProQR, in many ways. The company established proof of concept for the Axiomer® platform, a novel and proprietary RNA editing technology. “This opens up a whole new way of designing medicines for genetic diseases."